Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study

被引：0
|
作者：
Antoinette MaassenVanDenBrink
Gisela M. Terwindt
Joshua M. Cohen
Steve Barash
Verena Ramirez Campos
Maja Galic
Xiaoping Ning
Mikko Kärppä
机构：
[1] Erasmus University Medical Center Rotterdam,Division of Pharmacology and Vascular Medicine, Department of Internal Medicine
[2] Leiden University Medical Center,Department of Neurology
[3] Teva Pharmaceutical Products R&D,Research Unit of Clinical Neuroscience
[4] Inc.,undefined
[5] Teva Pharmaceuticals Europe B.V.,undefined
[6] University of Oulu and Medical Research Center,undefined
[7] Oulu University Hospital,undefined
来源：
The Journal of Headache and Pain | 2021年 / 22卷
关键词：
Fremanezumab; Calcitonin gene-related peptide; Age; Sex; Migraine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Impact of Fremanezumab on Migraine-associated Symptoms in Patients With Migraine Who Failed 2-4 Classes of Preventive Medications: Results of the Open-Label Period of the Phase 3b FOCUS Study
    Mechtler, L. L.
    Ning, X.
    Cohen, J. M.
    Ramirez-Campos, V
    Yang, R.
    HEADACHE, 2020, 60 : 19 - 19
  • [42] Pooled Analysis of Cardiovascular Safety of Fremanezumab in Patients ≥60 Years of Age With Migraine: Pooled Results of 3 Randomised, Double-blind, Placebo-controlled Phase 3 Studies
    Naegel, S.
    Cohen, J. M.
    Kessler, Y.
    Ning, X.
    Yang, R.
    Kudrow, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 1079 - 1080
  • [43] Very Early Onset of Action of Fremanezumab in Patients With Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Results of the International, Multicenter, Randomized, Placebo-controlled FOCUS Study
    Brandes, Jan Lewis
    Ramirez-Campos, Verena
    Yang, Ronghua
    Cohen, Joshua
    Galic, Maja
    Ning, Xiaoping
    Treppendahl, Christina
    NEUROLOGY, 2020, 94 (15)
  • [44] Efficacy of fremanezumab in patients with migraine and documented inadequate response to valproic acid and 2-3 other classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
    Pazdera, L.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Yang, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 633 - 633
  • [45] Prevention of difficult-to-treat menstrual migraine using a 6-day regimen of frovatriptan: A second double-blind, randomized, placebo-controlled trial
    Brandes, J. L.
    MacGregor, A.
    Silberstein, S. D.
    Tobin, J.
    Shaw, B.
    HEADACHE, 2007, 47 (05): : 789 - 790
  • [46] Clinically Meaningful Responses to Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications in the Multicenter, Randomized, Placebo-controlled FOCUS Study
    Spierings, E.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Yang, R.
    HEADACHE, 2019, 59 : 23 - 24
  • [47] Safety and Tolerability Outcomes of the Multicenter, Randomized, Placebo-controlled FOCUS Study of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications
    Ferrari, M. D.
    Cohen, J. M.
    Ning, X.
    Galic, M.
    Yang, R.
    HEADACHE, 2019, 59 : 116 - 117
  • [48] Clinically Meaningful Responses to Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medications in the Randomized, Placebo-controlled FOCUS Study
    Ashina, Sait
    Ramirez-Campos, Verena
    Cohen, Joshua
    Janka, Lindsay
    Spierings, Egilius L. H.
    NEUROLOGY, 2020, 94 (15)
  • [49] Efficacy of fremanezumab in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications: subgroup analysis of the randomised, placebo-controlled FOCUS study
    Silberstein, Stephen
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Yang, Ronghua
    Galic, Maja
    Ning, Xiaoping
    Jann, Adelene
    CEPHALALGIA, 2019, 39 : 226 - 227
  • [50] Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study
    Kashihara, Naoki
    Okada, Hirokazu
    Suzuki, Yusuke
    Iwamoto, Tamio
    Yasutomi, Masashi
    Matsui, Masaru
    Takezawa, Ryo
    Ishii, Takayuki
    Tomioka, Yusuke
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2025,
12345